TITLE

Pipeline

PUB. DATE
September 2010
SOURCE
Pharmaceutical Representative;Sep2010, Vol. 40 Issue 9, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to clinical trials of drugs. Amgen Inc. has been disappointed on the negative results of its Phase III trial evaluating Vectibix as treatment for cancer patients. The investigational oral hepatitis C protease inhibitor Boceprevir has met the primary endpoints in two Phase III trials. The negative results from the Phase III studies of semagacestat, a potential treatment for Alzheimer's disease, has prompted Eli Lilly and Co. to discontinue its development.
ACCESSION #
53550410

 

Related Articles

  • Amgen's Aranesp disappointing in breast cancer study.  // PharmaWatch: Cancer;Jan2008, Vol. 7 Issue 1, p9 

    The article reports on the results of a Phase III study conducted by Amgen Inc. for its Aranesp drug in the treatment of breast cancer. In a study of 733 neoadjuvant breast cancer patients, it showed numerically more deaths and tumor progression events on the Aranesp arm compared with the...

  • Lilly Reloads Solanezumab, Shoots for Mild Alzheimer's. Powers, Marie // BioWorld Today;7/15/2013, Vol. 24 Issue 133, p1 

    The article reports that Eli Lilly and Co. will undertake another clinical trials for solanezumab for the milder form of Alzheimer's disease (AD). In 2012, the drug missed both the cognitive and functional endpoints in its two double-blind, placebo controlled trials in patients with mild to...

  • Trial Design Meets Expectations.  // BioWorld Today;7/15/2013, Vol. 24 Issue 133, p4 

    The article examines Eli Lilly and Company's Expedition3, the second-phase clinical trial design for solanezumab for a milder form of Alzheimer's disease. Eli Lilly announced that the trial allows for, but does not require an interim analysis to be conducted by the data monitoring committee,...

  • news in brief.  // Nature;1/6/2005, Vol. 433 Issue 7021, p6 

    This article reports on developments in scientific research. One of them relates to the clinical trials of blockbuster drugs that have been made public by pharmaceutical company Eli Lilly & Co. The Indianapolis-based firm launched the online Lilly Clinical Trial Registry, which contains trial...

  • Lilly/Centocor: ReoPro falls at final hurdle.  // PharmaWatch: Biotechnology;Nov2005, Vol. 4 Issue 11, p7 

    The article focuses on the suspension of the enrollment of patients in a phase III trial evaluating ReoPro drug in ischemic stroke by Eli Lilly & Co. and Centocor Inc. It is observed that the new development may not harm Reopro's commercial potential since it is yet to win approval. Eli Lilly &...

  • Cytogen: another comforting combination for Quadramet.  // PharmaWatch: Biotechnology;Nov2005, Vol. 4 Issue 11, p8 

    The article focuses on a study which shows that a combination of Quadramet plus and Gemzar produced by Cytogen Corp. and Eli Lilly & Co. respectively, has demonstrated a positive clinical responses in advanced osteosarcoma. It is observed that the results are valuable for Cytogen since they have...

  • In spite of criticism, Lilly saves lives. Schenck, Steven J. // Indianapolis Business Journal;3/30/2009, Vol. 30 Issue 4, p11A 

    The author shares his views on the success of Indianapolis, Indiana-based drug company Eli Lilly & Co. in introducing the trial drug Enzastaurin, which has saved the life of his wife. He narrates how his wife suffering from glioblastoma was cured by a clinical trial using the drug. The author...

  • Improvement Seen in Neuropathy Patients Using Ruboxistaurin.  // Podiatry Management;Nov/Dec2004, Vol. 23 Issue 9, p240 

    Announces the results of the clinical trial conducted by Eli Lilly and Co. on the drug ruboxistaurin as a treatment for diabetic microvascular complications. Improvement in the symptoms of diabetic peripheral neuropathy (DPN) upon administration of the drug; Correlation of diabetic...

  • Alzheimer's failure raises questions about disease-modifying strategies. Extance, Andy // Nature Reviews Drug Discovery;Oct2010, Vol. 9 Issue 10, p749 

    The article reports on the termination of development of semagacestat, a y-secretase inhibitor which is a potential Alzheimer's disease (AD) treatment, by Eli Lilly & Co. It notes that preliminary results from long-term Phase III placebo-controlled studies showed that semagacestat failed to slow...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics